Figure 2From: Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY studyParticipant disposition. AML, amlodipine besylate; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil.Back to article page